B. Riley FBR Maintains Buy on Arrowhead Pharmaceuticals, Raises Price Target to $59

B. Riley FBR maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy and raises the price target from $46 to $59.

Benzinga · 11/13/2019 14:27

B. Riley FBR maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy and raises the price target from $46 to $59.